Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the market ...